ReviewFrontiers in immunology2023
Inhibition of T-cell activity in alopecia areata: recent developments and new directions.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Comparative Efficacy of Janus Kinase Inhibitors Indicated for Severe Alopecia Areata: A Bayesian Network Meta-Analysis and Matching-Adjusted Indirect Comparison.The Journal of dermatology · 2026Pooled it
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- A meta-analysis of chemokines in alopecia areata: recruiting immune cells toward the hair follicle.Frontiers in immunology · 2025Pooled it
- Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy.Allergy · 2025Trial
- Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Trial
- Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Trial
- A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata.Pharmacology research & perspectives · 2024Trial
- Rezpegaldesleukin and Regulatory T Cell Restoration in Immune-Mediated Skin Diseases.Dermatology and therapy · 2026Review
- Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study.Dermatology and therapy · 2026Article
- The CREM-IL-15 axis: decoding the persistence-exhaustion paradox in NK cell immunotherapy.Cancer immunology, immunotherapy : CII · 2026Review
- Exploring the potential of natural products in treating alopecia areata.Journal of pharmaceutical analysis · 2026Review
- The Concurrence of Atopic Dermatitis and Alopecia Areata: How Common Is It? Why Does It Happen? How Is This Managed Optimally in Clinical Practice?The Journal of clinical and aesthetic dermatology · 2026Review
- Cost-Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan.The Journal of dermatology · 2026Article
- Targeted inhibition of ITK activity with anti-CD3 antibody-modified calcium silicate nanoparticles loaded with novel 7H-Pyrrolo[2,3-d]pyrimidine derivatives for treating aplastic anemia.Journal of nanobiotechnology · 2026Article
- ROS-responsive hydrogel-delivered miR-665 targets STAT3 to alleviate inflammation and promote hair follicle regeneration in alopecia areata.Journal of nanobiotechnology · 2026Article
- Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib.Dermatology and therapy · 2026Article
- Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics.Journal of inflammation research · 2026Review
- Resident T cell activation leads to human hair follicle immune privilege lossFrontiers in medicine · 2026Article
- Immune checkpoint imbalance in ANCA-associated vasculitis: insights into disease activity and precision immunotherapy.Frontiers in medicine · 2026Review
- JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alopecia areata (AA) is an autoimmune disease that has a complex underlying immunopathogenesis characterized by nonscarring hair loss ranging from small bald patches to complete loss of scalp, face, and/or body hair. Although the etiopathogenesis of AA has not yet been fully characterized, immune privilege collapse at the hair follicle (HF) followed by T-cell receptor recognition of exposed HF autoantigens by autoreactive cytotoxic CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.